Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening - Nature
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening Nature
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS - The Manila Times
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS The Manila Times